Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | PLD2 | O14939 | 3/20 | 0.51 |
| ▸ | PLD1 | Q13393 | 3/20 | 0.51 |
| ▸ | CCR2 | P41597 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8220634 | 0.86 | TP53 (0.62) | TSHRMAPTTP53CYP3A4ALOX15 | |
| SCHEMBL3281974 | 0.84 | TP53 (0.60) | TSHRMAPTTP53CYP3A4ALOX15 | |
| SCHEMBL8011901 | 0.83 | TP53 (0.58) | TSHRMAPTTP53CYP3A4ALOX15 | |
| SCHEMBL1700111 | 0.82 | TP53 (0.56) | TSHRMAPTTP53CYP3A4ALOX15 | |
| SCHEMBL3973158 | 0.81 | TP53 (0.53) | TSHRMAPTTP53CYP3A4ALOX15 | |
| SCHEMBL31122179 | 0.80 | TSHR (0.74) | TSHRMAPTTP53CYP3A4ALOX15 | |
| SCHEMBL31122177 | 0.80 | TSHR (0.67) | TSHRMAPTTP53CYP3A4ALOX15 | |
| SCHEMBL10915131 | 0.79 | SIGMAR1 (0.66) | TSHRMAPTTP53CYP3A4ALOX15 | |
| SCHEMBL13314880 | 0.78 | PLD2 (0.58) | TSHRMAPTTP53CYP3A4ALOX15 | |
| SCHEMBL12926194 | 0.78 | TSHR (0.74) | TSHRMAPTTP53CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152176-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152176-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-17 | — | — | US | disclosed |
| US-7696201-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696201-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-13 | — | — | US | disclosed |
| US-20080176843-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-07-24 | — | — | US | disclosed |
| US-20080176843-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176843-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | TSHR 131/4885MAPT 2337/4885TP53 4383/4885 |
| US-20100152176-A1 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | TSHR 131/4885MAPT 2337/4885TP53 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.